Overview

A Pivotal Study to Evaluate the Efficacy of Lorundrostat (MLS-101) in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a standardized anti-hypertensive (AHT) medication regimen, in subjects with uncontrolled hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Mineralys Therapeutics Inc.